Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate

磷酸西格列汀一水合物/盐酸吡格列酮

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
Drug Alias Name西格列汀-吡格列酮Sitagliptin+PioglitazoneSitagliptin•Pioglitazone西格列汀和吡格列酮Pioglitazine/sitagliptin +[13] 
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IVPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Pioglitazone HydrochlorideSitagliptin Phosphate Monohydrate
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A